S
Stefan Barth
Researcher at University of Cape Town
Publications - 252
Citations - 4978
Stefan Barth is an academic researcher from University of Cape Town. The author has contributed to research in topics: Fusion protein & Immunotoxin. The author has an hindex of 34, co-authored 238 publications receiving 4509 citations. Previous affiliations of Stefan Barth include Fraunhofer Society & RWTH Aachen University.
Papers
More filters
Journal ArticleDOI
Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
A. Klimka,B. Matthey,R C Roovers,Stefan Barth,Jan-Willem Arends,Andreas Engert,Hennie R. Hoogenboom +6 more
TL;DR: A recombinant, human anti-CD30 single-chain variable fragment (scFv) antibody is set out to make, which may serve as a targeting moiety with reduced immunogenicity and more rapid tumour penetration in similar clinical applications.
Journal ArticleDOI
Compatible-Solute-Supported Periplasmic Expression of Functional Recombinant Proteins under Stress Conditions
TL;DR: A novel compatible-solute-guided expression and purification strategy for the expression of functional rIT directed to the periplasmic space of Escherichia coli and its binding properties and cytotoxic potency were confirmed by competitive experiments.
Journal ArticleDOI
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Andreas Engert,Volker Diehl,Volker Diehl,Roland Schnell,Roland Schnell,Andrea Radszuhn,Andrea Radszuhn,Maria Theresia Hatwig,Maria Theresia Hatwig,Silke Drillich,Silke Drillich,G. Schön,G. Schön,Heribert Bohlen,Heribert Bohlen,Hans Tesch,Hans Tesch,Martin L. Hansmann,Martin L. Hansmann,Stefan Barth,Stefan Barth,John Schindler,John Schindler,Victor Ghetie,Victor Ghetie,Jonathan W. Uhr,Ellen S. Vitetta +26 more
TL;DR: The anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, was used in a phase I dose escalation trial in patients with refractory Hodgkin's lymphoma, and data seem to indicate clinical efficacy of this new IT in heavily pretreated patients, thus warranting further clinical investigation.
Journal ArticleDOI
Cell-Specific Induction of Apoptosis by Rationally Designed Bivalent Aptamer-siRNA Transcripts Silencing Eukaryotic Elongation Factor 2
TL;DR: Specific cytotoxicity resulting from siRNA-induced silencing of EEF2, as well as specific delivery to PSMA-expressing prostate cancer cells are shown, demonstrating the usefulness of multivalent aptamer-based delivery vehicles for siRNA therapeutics.
Journal ArticleDOI
Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes
Bettina Stahnke,T. Thepen,Michael Stöcker,Reinhard Rosinke,Edgar Jost,Rainer Fischer,Mehmet Kemal Tur,Stefan Barth +7 more
TL;DR: This is the first report of a completely human granzyme B-based immunotoxin directed against CD64, with activity against an AML-related cell line and primary AML cells.